SGLT2 inhibitor improves CV outcomes in severe heart failure

The benefit was seen regardless of the presence of type 2 diabetes, researchers say
Medicom Staff writer

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020

The SGLT2 inhibitor empagliflozin is associated with a reduced risk of hospitalisation and death in patients who have heart failure with reduced ejection fraction (HFrEF), researchers have found.